AnGes MG Finally Starts Phase I Clinical Trial of NF-kappa B Decoy Oligodeoxynucleotide for Atopic Dermatitis.Tokyo, Japan, Oct 4, 2005 - (JCNN JCNN Japan Corporate News Network ) - AnGes MG has commenced a phase I clinical trial Noun 1. phase I clinical trial - a clinical trial on a few persons to determine the safety of a new drug or invasive medical device; for drugs, dosage or toxicity limits should be obtained phase I of NF-kappa B decoy DECOY. A pond used for the breeding and maintenance of water-fowl. 11 Mod. 74, 130; S. C. 3 Salk. 9; Holt, 14 11 East, 571. oligodeoxynucleotide. The clinical trial aims to seek the feasibility of NF-kappa B decoy oligodeoxynucleotide in the treatment of atopic dermatitis. The company has partnered with Alfresa Pharma in the trial. Currently, there are over 1.4 million people with atopic dermatitis in Japan, and no effective treatment for severe atopic dermatitis has yet to be established. Source: JCN JCN Japan Corporate News JCN Journal of Cognitive Neuroscience JCN Journal of Cardiovascular Nursing JCN Journal of Christian Nursing JCN Job Control Number JCN Journal of Child Neurology JCN joint communications network (US DoD) http://www.japancorp.net Copyright [c] 2005 Japan Corporate News Network. All rights reserved. |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion